Tamiflu (oseltamivir phosphate) NDC 0004-0822

NDC codes

FDA NDC Directory

Product NDC (as listed)0004-0822Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00004-0822Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0004-0822-05	00004082205	1 BOTTLE, GLASS in 1 CARTON (0004-0822-05) / 60 mL in 1 BOTTLE, GLASSMarketed from Mar 21, 2011

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Tamiflu
Generic name (nonproprietary): oseltamivir phosphate
Active ingredients: Oseltamivir phosphate — 6 mg/mL
Dosage form: Powder, For suspension
Route: Oral
Labeler: Genentech, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 021246
Marketing start: Mar 21, 2011
Listing expires: Dec 31, 2026
Other FDA classes: Neuraminidase Inhibitors (Mechanism)
Identifiers: Product ID 0004-0822_94a312ac-c47a-4437-8dd3-6bcd7e08e42cSPL ID 94a312ac-c47a-4437-8dd3-6bcd7e08e42cSPL set ID ee3c9555-60f2-4f82-a760-11983c86e97bRxCUI 261315, 312122, 728109, 728111, 728113, 728115, 1115698, 1115700UNII 4A3O49NGEZ
Pharmacologic class: Neuraminidase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400004082205 followed by a unit qualifier and the quantity

Package 00004-0822-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 15, 2025.

Indications (excerpt from the label)

TAMIFLU is an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. ( 1.1 ) Prophylaxis of influenza A and B in patients 1 year and older. ( 1.2 ) Limitations of Use : Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3 ) Not recommended for patients with end-stage renal disease not undergoing dialysis. ( 1.3 ) 1.1 Treatment of Influenza TAMIFLU is indicated for the treatment of acute, uncomplicated illness due to i…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)